Совет экспертов: «Новое в аллергологии»

1. Козулина И.Е., Курбачева О.М., Ильина Н.И. Аллергия сегодня. Анализ новых эпидемиологических данных. Рос. аллергол. журн. 2014; 3: 3–10. / Kozulina I.E., Kurbacheva O.M., Ilina N.I. Allergiia segodnia. Analiz novykh epidemiologicheskikh dannykh. Ros. allergol. zhurn. 2014; 3: 3–10. [in Russian]
2. Аллергология. Федеральные клинические рекомендации. Глав. ред. Р.М.Хаитов, Н.И.Ильина. М.: Фармарус Принт Медиа, 2014. / Allergologiia. Federalnye klinicheskie rekomendatsii. Glav. red. R.M.Khaitov, N.I.Ilina. M.: Farmarus Print Media, 2014. [in Russian]
3. Brozek JL, Bousquet J, Baena-Cagnani CE et al. Global Allergy and Asthma European Network; Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010; 126: 466–76.
4. Zuberbier T, Aberer W, Asero R et al. European Academy of Allergy and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014; 69: 868–87.
5. Федеральные клинические рекомендации. Дерматовенерология 2015. Болезни кожи. Инфекции, передаваемые половым путем. 5-е изд., перераб. и доп. М.: Деловой экспресс, 2016. / Federalnye klinicheskie rekomendatsii. Dermatovenerologiia 2015. Bolezni kozhi. Infektsii, peredavaemye polovym putem. 5-e izd., pererab. i dop. M.: Delovoi ekspress, 2016. [in Russian]
6. Инструкция по применению лекарственного препарата для медицинского применения Никсар® (рег. номер ЛП-003735-140716; утв. Минздравом России 14.07.2016). / Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Niksar® (reg. nomer LP-003735-140716; utv. Minzdravom Rossii 14.07.2016). [in Russian]
7. Corcostegui R et al. Preclinical pharmacology of bilastine, a new selective histamine H1-receptor antagonist. Receptor selectivity and in vitro antihistaminic activity. Drugs R D 2005; 6 (6): 371–84.
8. Alvarez-Mon M et al. Bilastine a novel antihistamine that preferentially inhibits histamine and interleukin-4 release from human mast cells and granulocytes. Allergy 2009; 64 (Suppl. 90): 555. XXVIII Congress of the European Academy of Allergology and Clinical Immunology. Warsaw (Poland) June 6–10, 2009. Abstract 1454.
9. Horak F et al. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res 2010; 59: 391–8.
10. Kuna P et al. Bilastine International Working Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy 2009; 39: 1338–47.
11. Bachert C et al. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 2009; 64 (1): 158–65.
12. Zuberbier T et al. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy 2010; 65 (4): 516–28.
13. Krause K et al. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy 2013; 68: 921–8.
14. Bousquet J et al. World Health Organization Collaborating Center for Asthma and Rhinitis. Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol 2012; 130: 1049–62.
15. Conen S et al. Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers. J Psychopharmacol 2011; 25: 1517–23.
16. Farre M et al. Bilastine vs. hydroxyzine: occupation of brain histamine H1-receptors evaluated by positron emission tomography in healthy volunteers. Br J Clin Pharmacol 2014; 78: 970–80.
17. García-Gea C et al. Psychomotor and subjective effects of bilastine, hydroxyzine, and cetirizine, in combination with alcohol: a randomized, double-blind, crossover, and positive-controlled and placebo-controlled Phase I clinical trials. Hum Psychopharmacol 2014; 29: 120–32.
18. Bousquet J et al. Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review. Curr Med Res Opin 2012; 28: 131–9.
19. Tyl B et al. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis. J Clin Pharmacol 2012; 52: 893–903.
20. Sastre J et al. Bilastine Study Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis. Curr Med Res Opin 2012; 28: 121–30.

________________________________________________

1. Kozulina I.E., Kurbacheva O.M., Ilina N.I. Allergiia segodnia. Analiz novykh epidemiologicheskikh dannykh. Ros. allergol. zhurn. 2014; 3: 3–10. [in Russian]
2. Allergologiia. Federalnye klinicheskie rekomendatsii. Glav. red. R.M.Khaitov, N.I.Ilina. M.: Farmarus Print Media, 2014. [in Russian]
3. Brozek JL, Bousquet J, Baena-Cagnani CE et al. Global Allergy and Asthma European Network; Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010; 126: 466–76.
4. Zuberbier T, Aberer W, Asero R et al. European Academy of Allergy and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014; 69: 868–87.
5. Federalnye klinicheskie rekomendatsii. Dermatovenerologiia 2015. Bolezni kozhi. Infektsii, peredavaemye polovym putem. 5-e izd., pererab. i dop. M.: Delovoi ekspress, 2016. [in Russian]
6. Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Niksar® (reg. nomer LP-003735-140716; utv. Minzdravom Rossii 14.07.2016). [in Russian]
7. Corcostegui R et al. Preclinical pharmacology of bilastine, a new selective histamine H1-receptor antagonist. Receptor selectivity and in vitro antihistaminic activity. Drugs R D 2005; 6 (6): 371–84.
8. Alvarez-Mon M et al. Bilastine a novel antihistamine that preferentially inhibits histamine and interleukin-4 release from human mast cells and granulocytes. Allergy 2009; 64 (Suppl. 90): 555. XXVIII Congress of the European Academy of Allergology and Clinical Immunology. Warsaw (Poland) June 6–10, 2009. Abstract 1454.
9. Horak F et al. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res 2010; 59: 391–8.
10. Kuna P et al. Bilastine International Working Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy 2009; 39: 1338–47.
11. Bachert C et al. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 2009; 64 (1): 158–65.
12. Zuberbier T et al. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy 2010; 65 (4): 516–28.
13. Krause K et al. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy 2013; 68: 921–8.
14. Bousquet J et al. World Health Organization Collaborating Center for Asthma and Rhinitis. Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol 2012; 130: 1049–62.
15. Conen S et al. Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers. J Psychopharmacol 2011; 25: 1517–23.
16. Farre M et al. Bilastine vs. hydroxyzine: occupation of brain histamine H1-receptors evaluated by positron emission tomography in healthy volunteers. Br J Clin Pharmacol 2014; 78: 970–80.
17. García-Gea C et al. Psychomotor and subjective effects of bilastine, hydroxyzine, and cetirizine, in combination with alcohol: a randomized, double-blind, crossover, and positive-controlled and placebo-controlled Phase I clinical trials. Hum Psychopharmacol 2014; 29: 120–32.
18. Bousquet J et al. Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review. Curr Med Res Opin 2012; 28: 131–9.
19. Tyl B et al. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis. J Clin Pharmacol 2012; 52: 893–903.
20. Sastre J et al. Bilastine Study Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis. Curr Med Res Opin 2012; 28: 121–30.